# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number k192517   
B Applicant Psychemedics Corporation   
C Proprietary and Established Names Psychemedics Microplate EIA for Cotinine in Hair   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>MKU</td><td rowspan=1 colspan=1>Class I, meets the limitation tothe exemption 21 CFR862.9(a) and 862.9(b)</td><td rowspan=1 colspan=1>21 CFR 862.3220 -Carbon MonoxideTest System</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New device   
B Measurand: Cotinine   
C Type of Test:

Qualitative screening test: enzyme immunoassay (EIA) Quantitative confirmatory test: LC/MS/MS

# III Intended Use/Indications for Use:

A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

The Psychemedics Microplate EIA For Cotinine in Hair is an in vitro diagnostic device for the qualitative detection of cotinine in human head and body hair as an aid in the detection of cotinine after use or exposure to tobacco products. The assay is intended for a single site and uses a cutoff calibrator of $2 0 0 ~ \mathrm { p g }$ cotinine/mg hair. This device is intended exclusively for Psychemedics use only and is not intended for sale to anyone.

The Psychemedics Microplate EIA For Cotinine in Hair provides only a preliminary analytical test result. A more specific alternate chemical method must be used to obtain a confirmed analytical result. Liquid Chromatography/Mass spectrometry/Mass spectrometry (LC/MS/MS) is the confirmatory method used by Psychemedics Corporation. The LC/MS/MS analysis uses a cutoff, after extensive washing of the hair, of $1 0 0 ~ \mathrm { p g }$ cotinine/mg hair with presence of hydroxycotinine at or above $1 0 ~ \mathrm { p g / m g }$ hair.

C Special Conditions for Use Statement(s):

OTC - Over The Counter

# D Special Instrument Requirements:

The Psychemedics Microplate EIA For Cotinine in Hair assay requires a Microplate Reader with $4 5 0 \mathrm { n m }$ and $6 3 0 ~ \mathrm { n m }$ wavelength absorbance capability.

The confirmation assay uses an AB Sciex API-3200 LC/MS/MS linked to a Shimadzu LC20-AD binary pump system with a CBM 20A communications bus module and a DGU-20A5R degassing unit. The autosampler is a PAL- HTC-xt.

# IV Device/System Characteristics:

# A Device Description:

The Psychemedics Microplate EIA for Cotinine in Hair is an enzyme immunoassay (EIA) for the preliminary qualitative detection of cotinine in human hair samples using a $2 . 0 \mathrm { n g }$ cotinine/10 mg hair $( 2 0 0 ~ \mathrm { p g / m g }$ hair) cutoff for the purpose of identifying nicotine use. To confirm a preliminary positive result for the presence of cotinine, LC/MS/MS must be used in addition to this preliminary test.

The Psychemedics Microplate EIA for Cotinine in Hair assay consists of:

• BSA-cotinine coated Microplate   
• Cutoff calibrator and the controls around the cutoff   
• Primary antibody against cotinine   
• HRP-labeled secondary antibody directed against the primary antibody species   
• Substrate TMB (tetramethylbenzidine)   
• Acidic stop solution (2 N HCl)

The confirmation assay consists of calibrators and an AB Sciex API-3200 LC/MS/MS linked to a Shimadzu LC20-AD binary pump system with a CBM 20A communications bus module and a DGU-20A5R degassing unit. The autosampler is a PAL- HTC-xt.

# B Principle of Operation:

The Psychemedics Microplate EIA for Cotinine in Hair is based upon the competitive binding with the antibody to cotinine in the sample and solid-phase cotinine in the microplate wells, in proportion to their relative concentrations.

Hair samples are cut as close as possible to the skin, packaged and shipped at ambient temperature to the laboratory, where they are digested in a solution containing $0 . 3 \%$ dithiothreitol at $\mathsf { p H } 9 . 5$ for two hours, then neutralized. Hair sample extracts and primary antibody are combined in the wells (coated with cotinine-BSA conjugate) and incubated. After washing, secondary antibody-HRP is added and the plate incubated 1 hour. After washing, substrate is added, and, after a final incubation, the wells are acidified and read with the microplate absorbance reader at $4 5 0 \ \mathrm { n m }$ with background set at $6 3 0 \ \mathrm { n m } .$ Results are normalized by expression as $\mathrm { B } / \mathrm { B } 0 \mathrm { ~ x ~ } 1 0 0$ . If cotinine is present in the sample, less primary antibody will be bound to the solid-phase antigen, thereby resulting in less binding of HRP-labeled secondary antibody; the absorbance produced is inversely proportional to the amount of cotinine in the sample (specimen, calibrator or control).

For samples that are presumptive positive by the screening assay, a new aliquot of the hair sample is weighed, washed extensively to remove externally-derived cotinine, extracted by a different procedure, and confirmed by LC/MS/MS for the presence of cotinine and hydroxycotinine.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Micro-plate Cotinine EIA B Predicate 510(k) Number(s): K974534

# C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>k192517</td><td rowspan=1 colspan=1>k974534</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>Psychemedics MicroplateEIA for Cotinine in Hair</td><td rowspan=1 colspan=1>Orasure CotinineSerumMicroplate EIA</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacte ris tic Similaritie s</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For the detection ofCotinine. The assayprovides only apreliminary analytical testresult. A more specificalternative chemicalmethod must be used inorder to obtain aconfirmed analyticalresult.</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>MKU</td></tr><tr><td rowspan=1 colspan=1>Me as urand</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Cotinine</td></tr><tr><td rowspan=1 colspan=1>Me thod of Me as ure ment</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Microplate reader, read at450 nm</td></tr><tr><td rowspan=1 colspan=1>Type of Test</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Enzyme Immunoassay</td></tr><tr><td rowspan=1 colspan=1>Confirmation Method</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>LC/MS/MS</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacte ris tic Diffe re nces</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>Human Hair</td><td rowspan=1 colspan=1>Human Serum</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>2 ng cotinine/10 mg hair(200 pg cotinine /mg hair)</td><td rowspan=1 colspan=1>10 ng /mL</td></tr><tr><td rowspan=1 colspan=1>Extraction Method</td><td rowspan=1 colspan=1>Patented Digestion method</td><td rowspan=1 colspan=1>No extraction method</td></tr></table>

# VI Standards/Guidance Documents Referenced:

None referenced.

VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

# Precision of the Psychemedics Microplate EIA for Cotinine in Hair assay

The analytical precision around the cut-off ${ ( 2 0 0 \ \mathrm { p g / m g } }$ hair) for cotinine was determined. Ten replicate hair samples each were spiked before digestion at the cutoff and at $\pm 2 5 \%$ , $\pm 5 0 \% , \pm 7 5 \%$ a $1 \mathrm { { d } } \pm 1 0 0 \%$ of the cutoff concentration of $2 0 0 ~ \mathrm { p g }$ cotinine/mg hair. The results of this intra-assay precision analysis are shown on the left side of the table below. The same procedure was carried out for 5 days to determine inter-assay precision. These results are shown in the table on the right.

<table><tr><td rowspan=1 colspan=3>Summary -Intra-Assay Precision</td><td></td><td rowspan=3 colspan=3></td><td rowspan=1 colspan=3>Summary-Inter-Assay Precision</td></tr><tr><td rowspan=1 colspan=1>LEVEL</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td><td></td><td rowspan=1 colspan=1>LEVEL</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Bo(-100%)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Bo(-100%)</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=3 colspan=4></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-75%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>plus 25%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=2 colspan=4></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>plus 25%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>plus 50%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>plus 50%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>plus 75%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=2 colspan=4></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>plus 75%</td></tr><tr><td rowspan=1 colspan=1>plus 100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>plus 100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td></tr></table>

# Precision of the LC-MS/MS method

Within-run precision around the LC/MS/MS cutoff was conducted using drug negative hair samples spiked with 0, 10, 20, 35, 50, 80, 100, 300, 500, 700, $1 0 0 0 ~ \mathrm { p g / m g }$ hair of cotinine. Samples were prepared in replicates of 5, per each concentration for cotinine and hydroxycotinine, and run over 5 days. Results for the cotinine and hydroxycotinine measured by the LC-MS/MS assay, are summarized below.

<table><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="5">Cotinine (pg/mghair)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">11.51</td><td colspan="1" rowspan="1">19.75</td><td colspan="1" rowspan="1">37.67</td><td colspan="1" rowspan="1">52.29</td><td colspan="1" rowspan="1">82.11</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">10.04</td><td colspan="1" rowspan="1">20.74</td><td colspan="1" rowspan="1">36.27</td><td colspan="1" rowspan="1">51.14</td><td colspan="1" rowspan="1">84.74</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">10.16</td><td colspan="1" rowspan="1">21.61</td><td colspan="1" rowspan="1">38.72</td><td colspan="1" rowspan="1">56.48</td><td colspan="1" rowspan="1">85.71</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">11.47</td><td colspan="1" rowspan="1">22.65</td><td colspan="1" rowspan="1">38.45</td><td colspan="1" rowspan="1">51.52</td><td colspan="1" rowspan="1">82.56</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">11.72</td><td colspan="1" rowspan="1">20.98</td><td colspan="1" rowspan="1">37.5</td><td colspan="1" rowspan="1">51.1</td><td colspan="1" rowspan="1">81.08</td></tr><tr><td colspan="1" rowspan="1">Average</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">11.0</td><td colspan="1" rowspan="1">21.1</td><td colspan="1" rowspan="1">37.7</td><td colspan="1" rowspan="1">52.5</td><td colspan="1" rowspan="1">83.2</td></tr><tr><td colspan="1" rowspan="1">S.D.</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.41</td><td colspan="1" rowspan="1">1.77</td><td colspan="1" rowspan="1">2.58</td><td colspan="1" rowspan="1">1.60</td><td colspan="1" rowspan="1">2.78</td></tr><tr><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">3.76</td><td colspan="1" rowspan="1">8.35</td><td colspan="1" rowspan="1">6.85</td><td colspan="1" rowspan="1">3.05</td><td colspan="1" rowspan="1">3.34</td></tr><tr><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">10.62 -11.34</td><td colspan="1" rowspan="1">19.6 -22.69</td><td colspan="1" rowspan="1">35.46 -39.99</td><td colspan="1" rowspan="1">51.1 -53.91</td><td colspan="1" rowspan="1">80.81 -85.68</td></tr><tr><td colspan="1" rowspan="1">% of Target</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">109.8</td><td colspan="1" rowspan="1">105.7</td><td colspan="1" rowspan="1">107.8</td><td colspan="1" rowspan="1">105.0</td><td colspan="1" rowspan="1">104.1</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">700</td><td colspan="1" rowspan="1">1000</td></tr><tr><td colspan="1" rowspan="5">Cotinine (pg/mghair)</td><td colspan="1" rowspan="1">82.11</td><td colspan="1" rowspan="1">108.35</td><td colspan="1" rowspan="1">296.07</td><td colspan="1" rowspan="1">497.93</td><td colspan="1" rowspan="1">712.54</td><td colspan="1" rowspan="1">982.12</td></tr><tr><td colspan="1" rowspan="1">84.74</td><td colspan="1" rowspan="1">102.85</td><td colspan="1" rowspan="1">295.45</td><td colspan="1" rowspan="1">491.4</td><td colspan="1" rowspan="1">706.34</td><td colspan="1" rowspan="1">1001.78</td></tr><tr><td colspan="1" rowspan="1">85.71</td><td colspan="1" rowspan="1">100.42</td><td colspan="1" rowspan="1">310.71</td><td colspan="1" rowspan="1">503.78</td><td colspan="1" rowspan="1">694.01</td><td colspan="1" rowspan="1">973.54</td></tr><tr><td colspan="1" rowspan="1">82.56</td><td colspan="1" rowspan="1">100.71</td><td colspan="1" rowspan="1">301.65</td><td colspan="1" rowspan="1">519.56</td><td colspan="1" rowspan="1">683.05</td><td colspan="1" rowspan="1">969.02</td></tr><tr><td colspan="1" rowspan="1">81.08</td><td colspan="1" rowspan="1">105.58</td><td colspan="1" rowspan="1">316.6</td><td colspan="1" rowspan="1">491.73</td><td colspan="1" rowspan="1">691.6</td><td colspan="1" rowspan="1">1016.93</td></tr><tr><td colspan="1" rowspan="1">Average</td><td colspan="1" rowspan="1">83.2</td><td colspan="1" rowspan="1">103.6</td><td colspan="1" rowspan="1">304.1</td><td colspan="1" rowspan="1">500.9</td><td colspan="1" rowspan="1">697.5</td><td colspan="1" rowspan="1">988.7</td></tr><tr><td colspan="1" rowspan="1">S.D.</td><td colspan="1" rowspan="1">2.78</td><td colspan="1" rowspan="1">2.40</td><td colspan="1" rowspan="1">13.59</td><td colspan="1" rowspan="1">9.59</td><td colspan="1" rowspan="1">17.22</td><td colspan="1" rowspan="1">32.87</td></tr><tr><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">3.34</td><td colspan="1" rowspan="1">2.32</td><td colspan="1" rowspan="1">4.47</td><td colspan="1" rowspan="1">1.91</td><td colspan="1" rowspan="1">2.47</td><td colspan="1" rowspan="1">3.33</td></tr><tr><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">80.81-85.68</td><td colspan="1" rowspan="1">101.48 -105.69</td><td colspan="1" rowspan="1">292.18 316.01</td><td colspan="1" rowspan="1">492.47 -316.01</td><td colspan="1" rowspan="1">682.42712.6</td><td colspan="1" rowspan="1">959.86 -1017-49</td></tr><tr><td colspan="1" rowspan="1">% of Target</td><td colspan="1" rowspan="1">104.1</td><td colspan="1" rowspan="1">103.6</td><td colspan="1" rowspan="1">101.4</td><td colspan="1" rowspan="1">100.2</td><td colspan="1" rowspan="1">99.6</td><td colspan="1" rowspan="1">98.9</td></tr></table>

<table><tr><td rowspan=5 colspan=1>Hydroxycotinine(pg/mg hair)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>34.6</td><td rowspan=1 colspan=1>48.2</td><td rowspan=1 colspan=1>76.7</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>32.2</td><td rowspan=1 colspan=1>49.4</td><td rowspan=1 colspan=1>77.8</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>21.1</td><td rowspan=1 colspan=1>32.3</td><td rowspan=1 colspan=1>50.4</td><td rowspan=1 colspan=1>72.5</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>23.9</td><td rowspan=1 colspan=1>31.7</td><td rowspan=1 colspan=1>49.7</td><td rowspan=1 colspan=1>71.2</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11.8</td><td rowspan=1 colspan=1>19.4</td><td rowspan=1 colspan=1>37.9</td><td rowspan=1 colspan=1>46.3</td><td rowspan=1 colspan=1>75.4</td></tr><tr><td rowspan=1 colspan=1>Average</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>33.7</td><td rowspan=1 colspan=1>48.8</td><td rowspan=1 colspan=1>74.7</td></tr><tr><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>2.58</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>2.78</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>3.71</td><td rowspan=1 colspan=1>8.41</td><td rowspan=1 colspan=1>7.65</td><td rowspan=1 colspan=1>3.28</td><td rowspan=1 colspan=1>3.72</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>10.77 -11.50</td><td rowspan=1 colspan=1>19.45 -22.54</td><td rowspan=1 colspan=1>31.48 -36.01</td><td rowspan=1 colspan=1>47.39 -50.2</td><td rowspan=1 colspan=1>72.27 -77.14</td></tr><tr><td rowspan=1 colspan=1>% of Target</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>111.4</td><td rowspan=1 colspan=1>105.0</td><td rowspan=1 colspan=1>96.4</td><td rowspan=1 colspan=1>97.6</td><td rowspan=1 colspan=1>93.4</td></tr></table>

<table><tr><td rowspan=5 colspan=1>Hydroxycotinine(pg/mg hair)</td><td rowspan=1 colspan=1>76.7</td><td rowspan=1 colspan=1>97.3</td><td rowspan=1 colspan=1>280.2</td><td rowspan=1 colspan=1>482.4</td><td rowspan=1 colspan=1>610.0</td><td rowspan=1 colspan=1>848.2</td></tr><tr><td rowspan=1 colspan=1>77.8</td><td rowspan=1 colspan=1>94.2</td><td rowspan=1 colspan=1>249.6</td><td rowspan=1 colspan=1>462.2</td><td rowspan=1 colspan=1>646.6</td><td rowspan=1 colspan=1>911.9</td></tr><tr><td rowspan=1 colspan=1>72.5</td><td rowspan=1 colspan=1>91.5</td><td rowspan=1 colspan=1>280.6</td><td rowspan=1 colspan=1>466.5</td><td rowspan=1 colspan=1>638.4</td><td rowspan=1 colspan=1>909.7</td></tr><tr><td rowspan=1 colspan=1>71.2</td><td rowspan=1 colspan=1>93.2</td><td rowspan=1 colspan=1>281.8</td><td rowspan=1 colspan=1>468.1</td><td rowspan=1 colspan=1>637.7</td><td rowspan=1 colspan=1>897.3</td></tr><tr><td rowspan=1 colspan=1>75.4</td><td rowspan=1 colspan=1>96.6</td><td rowspan=1 colspan=1>274.9</td><td rowspan=1 colspan=1>482.9</td><td rowspan=1 colspan=1>610.3</td><td rowspan=1 colspan=1>937.4</td></tr><tr><td rowspan=1 colspan=1>Average</td><td rowspan=1 colspan=1>74.7</td><td rowspan=1 colspan=1>94.6</td><td rowspan=1 colspan=1>273.4</td><td rowspan=1 colspan=1>472.4</td><td rowspan=1 colspan=1>628.6</td><td rowspan=1 colspan=1>900.9</td></tr><tr><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>2.78</td><td rowspan=1 colspan=1>2.40</td><td rowspan=1 colspan=1>13.59</td><td rowspan=1 colspan=1>9.59</td><td rowspan=1 colspan=1>17.22</td><td rowspan=1 colspan=1>32.87</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>3.72</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>4.97</td><td rowspan=1 colspan=1>2.03</td><td rowspan=1 colspan=1>2.74</td><td rowspan=1 colspan=1>3.65</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>72.27-77.14</td><td rowspan=1 colspan=1>92.46 -96.66</td><td rowspan=1 colspan=1>261.49 -285.32</td><td rowspan=1 colspan=1>464.02 -480.83</td><td rowspan=1 colspan=1>613.49-643.67</td><td rowspan=1 colspan=1>872.09 -929.72</td></tr><tr><td rowspan=1 colspan=1>% of Target</td><td rowspan=1 colspan=1>93.4</td><td rowspan=1 colspan=1>94.6</td><td rowspan=1 colspan=1>91.1</td><td rowspan=1 colspan=1>94.5</td><td rowspan=1 colspan=1>89.8</td><td rowspan=1 colspan=1>90.1</td></tr></table>

The screening immunoassay is a qualitative test only; therefore, a linearity evaluation is not applicable.

# Linearity of the LC-MS/MS confirmation method

The linearity of the confirmation method was evaluated by spiking cotinine and hydroxycotinine into negative hair over the range of 0 to $1 0 0 0 ~ \mathrm { p g / m g }$ hair. Eleven concentrations within this range were evaluated (0, 10, 20, 35, 50, 80, 100, 300, 500, 700, $1 0 0 0 ~ \mathrm { p g / m g }$ hair). All levels for cotinine and hydroxycotinine demonstrated percent recoveries within $+ / - ~ 1 5 \%$ of the expected value.

3. Analytical Specificity/Interference:

# Specificity of the immunoassay screening method

# Immunoassay: Cross-reactivity with structurally related compounds

The cross-reactivity characteristics of the screening immunoassay was evaluated by spiking various concentrations of cotinine into drug-free hair samples and comparing the result to the cutoff calibrator. The table below lists the percent cross-reactivity and the approximate concentration of each compound required to produce a response approximately equivalent to the cutoff concentration of the assay.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Percent Cross-reactivity</td><td rowspan=1 colspan=1>Expected ConcentrationEquivalent to 200 pgcotinine/mghair</td></tr><tr><td rowspan=1 colspan=1>Cotinine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Trans-3-hydroxycotinine</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>400</td></tr><tr><td rowspan=1 colspan=1>Nicotine</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>50,000</td></tr><tr><td rowspan=1 colspan=1>(S)  N- nitrosoanatabine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,0000</td></tr><tr><td rowspan=1 colspan=1>(+)-anabasine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,000</td></tr><tr><td rowspan=1 colspan=1>(+/-)-nornicotine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,000</td></tr><tr><td rowspan=1 colspan=1>(S)-nitrosoanabasine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,000</td></tr><tr><td rowspan=1 colspan=1>(+/-)-N-Nitrosonornicotine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,000</td></tr></table>

The following compounds were found to have no cross-reactivity in the assay.

Glutethimide, Meprobamate, Methyprylon, Flurazepam, Lorazepam, Medazepam, Temazepam, Carbamazepine, Diazepam, Nordiazepam, Oxazepam, Acetaminophen, Caffeine, Dyphylline, Methaqualone, Theophylline, ethosuximide, a-methyl-a-propylsuccimide, metharbital, barbital, methsuximide, phensuximide, N-Normethsuximide, Mephenytoin, Ethotoin, Mephobarbital, PEMA, Phenobarbital, Methyl PEMA, 10,11-Dihydrocarbamazepine, Primidone, Carbamazepine, 5,5-Diphenylhydantoin, 4-Methylprimidone, Haloperidol, Ibuprofen, LSD, Meperidine, Methadone, Methaqualone, Methylphenidate, Naloxone, Naltrexone, Naproxen, Nicotine, Nortriptyline, Propoxyphene, R,R Pseudoephedrine, Thioridazine, Cis-Tramadol, Venlafaxine hydochloride, 8(-)-11-nor-9-Carboxy-delta9 THC, 11-nor-9-Carboxy-delta9-THC, Delta 8-THC, Streptomycin solution, Benzocaine, Erythromycin, Penicillin G, Mepivacaine, Phendimetrazine bitartrate, Despropionyl, fentanyl, $( + / - )$ epinephrine, $( + / - )$ norepinephrine, $( + / - )$ metanephrine, $( + / - )$ normetanephrine, $( + / - )$ vanilmandelic acid, 5-hydroxyindole-3-acetic acid, homovanillic acid, Benzoylecgonine, Cocaethylene, Ecgonine Methyl Ester, $( + / .$ -)Methamphetamine, Cocaine, Heroin, $( + / - )$ methadone, codeine, hydrocodone, meperidine, oxycodone, AM2201 Spice, JWH-019 Spice, JWH-081 Spice, JWH-122 Spice, CP 47, 497 $( + / - )$ Spice, C8 homologue Spice, HU-211 Spice, JWH-200 Spice, JWH-250 Spice, acetaminophen, caffeine, chlorphenirame maleate, ibuprofen, naproxen, $\mathrm { R , R ( - ) }$ -pseudoephedrine, Medazepam, Oxazepam, Lorazepam, Diazepam, Temazepam, Bromazepam, Cocaethylene, Cocaine, $( + / - )$ methadone, buprenorphine, cis-tramadol HCl, codeine, fentanyl, hydrocodone, hydromorphone, meperidine, morphine, naloxone, naltrexone, oxymorphone, Amitriptyline, Desipramine, Doxepin,Imipramine, Nordoxepin, Nortiptyline, Protriptyline, Trimipramine, glutethimide, meprobromate, methylprylon, Amphetamine, Caffeine, Imipramine, Methamphetamine, Phencyclidine, Phenmetrazine, Phenylpropanolamine, Butabarital, Amobarbital, Secobarbital, Hexobarbital, Phenobarbital, Amitriptyline, Dextromethorphan, Lidocaine, Methocarbamol, Nordoxepin, Pentazocine, Phenylephrine, Triamterene, Amoxicillin, Propanolol, Promethazine, Phenmetrazine, Phendimetrazine, Benzocaine, Ecgononine, Metanephrin, Ethylmorphine, Nalorphine.

Compounds related to cotinine and tested for cross-reactivity with the antibody are listed in the table below.

Cross-Reactivity of Cotinine-Related Drugs   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Percent Cross-reactivity</td><td rowspan=1 colspan=1>Expected ConcentrationEquivalent to 200 pgcotinine/mghair</td></tr><tr><td rowspan=1 colspan=1>Cotinine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Trans-3-hydroxycotinine</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>400</td></tr><tr><td rowspan=1 colspan=1>Nicotine</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>50,000</td></tr><tr><td rowspan=1 colspan=1>(S)  N- nitrosoanatabine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,0000</td></tr><tr><td rowspan=1 colspan=1>(+)-anabasine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,000</td></tr><tr><td rowspan=1 colspan=1>(+/-)-nornicotine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,000</td></tr><tr><td rowspan=1 colspan=1>(S)-nitrosoanabasine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,000</td></tr><tr><td rowspan=1 colspan=1>(+/-)-N-Nitrosonornicotine</td><td rowspan=1 colspan=1>&lt; 1%</td><td rowspan=1 colspan=1>&gt;100,000</td></tr></table>

# Immunoassay: Interference from structurally unrelated compounds

The following potentially interfering compounds were tested using the screening immunoassay on samples spiked with cotinine above and below the cutoff to assess possible positive or negative interference. All potential interferents listed below were tested at a concentration of $1 0 0 ~ \mathrm { n g / 1 0 ~ m g }$ hair. No positive or negative interference was observed in this study.

<table><tr><td rowspan=1 colspan=1>10,11-Dihydrocarbamazepine</td><td rowspan=1 colspan=1>Cocaethylene</td><td rowspan=1 colspan=1>HU-211</td><td rowspan=1 colspan=1>metharbital</td><td rowspan=1 colspan=1>Phenmetrazine</td></tr><tr><td rowspan=1 colspan=1>11-nor-9-Carboxy-delta9-THC</td><td rowspan=1 colspan=1>Cocaine</td><td rowspan=1 colspan=1>hydrocodone</td><td rowspan=1 colspan=1>Methocarbamol</td><td rowspan=1 colspan=1>Phenmetrazine</td></tr><tr><td rowspan=1 colspan=1>4-Methylprimidone</td><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>methsuximide</td><td rowspan=1 colspan=1>Phenobarbital</td></tr><tr><td rowspan=1 colspan=1>5,5-Diphenylhydantoin</td><td rowspan=1 colspan=1>CP 47, 497 (+/-),C8 homologue</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>Methyl PEMA</td><td rowspan=1 colspan=1>phensuiximide</td></tr><tr><td rowspan=1 colspan=1>5-hydroxyindole-3-acetic acid</td><td rowspan=1 colspan=1>Delta 8-THC</td><td rowspan=1 colspan=1>Imipramine</td><td rowspan=1 colspan=1>Methyl phenidate</td><td rowspan=1 colspan=1>Phenylephrine</td></tr><tr><td rowspan=1 colspan=1>11-nor-9-Carboxy-delta9 THC</td><td rowspan=1 colspan=1>Desipramine</td><td rowspan=1 colspan=1>JWH-019</td><td rowspan=1 colspan=1>Methyprylon</td><td rowspan=1 colspan=1>Phenylpropanolamine</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>Despropionylfentanyl</td><td rowspan=1 colspan=1>JWH-081</td><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>Primidone</td></tr><tr><td rowspan=1 colspan=1>AM2201</td><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>JWH-122</td><td rowspan=1 colspan=1>Nalorphine</td><td rowspan=1 colspan=1>Procaine</td></tr><tr><td rowspan=1 colspan=1>a-methyl-a-propylsuccimide</td><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>JWH-200</td><td rowspan=1 colspan=1>Naloxone</td><td rowspan=1 colspan=1>Promethazine</td></tr><tr><td rowspan=1 colspan=1>Amitriptyline</td><td rowspan=1 colspan=1>Doxepin</td><td rowspan=1 colspan=1>JWH-250</td><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>Propanolol</td></tr><tr><td rowspan=1 colspan=1>Amobarbital</td><td rowspan=1 colspan=1>Dyphylline</td><td rowspan=1 colspan=1>Lidocaine</td><td rowspan=1 colspan=1>Naproxen</td><td rowspan=1 colspan=1>Propoxyphene</td></tr><tr><td rowspan=1 colspan=1>Amoxicillin</td><td rowspan=1 colspan=1>Ecgonine MethylEster</td><td rowspan=1 colspan=1>Lorazepam</td><td rowspan=1 colspan=1>N-Normethsuximide</td><td rowspan=1 colspan=1>Protriptyline</td></tr><tr><td rowspan=1 colspan=1>Amphetamine</td><td rowspan=1 colspan=1>Ecgononine</td><td rowspan=1 colspan=1>LSD</td><td rowspan=1 colspan=1>Nordiazepam</td><td rowspan=1 colspan=1>R,R(-)-pseudoephedrine</td></tr><tr><td rowspan=1 colspan=1>barbital</td><td rowspan=1 colspan=1>epinephrine (+/-)</td><td rowspan=1 colspan=1>Medazepam</td><td rowspan=1 colspan=1>Nordoxepin</td><td rowspan=1 colspan=1>Secobarbital</td></tr><tr><td rowspan=1 colspan=1>Barbiturates</td><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>Meperidine</td><td rowspan=1 colspan=1>Nordoxepin</td><td rowspan=1 colspan=1>Sedatives</td></tr><tr><td rowspan=1 colspan=1>Batubarbital</td><td rowspan=1 colspan=1>Ethosuximide</td><td rowspan=1 colspan=1>Mephenytoin</td><td rowspan=1 colspan=1>norepinephrine(+/-)</td><td rowspan=1 colspan=1>streptomycin</td></tr><tr><td rowspan=1 colspan=1>Benzocaine</td><td rowspan=1 colspan=1>Ethotoin</td><td rowspan=1 colspan=1>Mephobarbital</td><td rowspan=1 colspan=1>normetanephrine(+/-)</td><td rowspan=1 colspan=1>Temazepam</td></tr><tr><td rowspan=1 colspan=1>Benzoylecgonine</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mepivacaine</td><td rowspan=1 colspan=1>Nortriptyline</td><td rowspan=1 colspan=1>Theophylline</td></tr></table>

# Immunoassay: Effect of cosmetic treatments

Hair samples negative for cotinine and samples positive for cotinine were treated with the following cosmetic treatments: permanent wave, relaxer, dye (which includes bleach), and shampoo. After the treatments, these samples and an aliquot of the same hair samples untreated were digested for cotinine analysis and then assayed by the Psychemedics Microplate EIA for Cotinine in Hair. The EIA results with and without treatment are compared to detect interference in the assay or loss of drug due to the treatments. The study included 5 negative samples and 6 previously confirmed cotinine-positive samples with each type of treatment. Negative hair samples remained negative and positive samples remained positive after treatment with the cosmetic products for dye, shampoo, perm, or relaxing.

Effects of Cosmetic Treatments on Cotinine EIA Analysis of Cotinine-Negative Hair Samples   

<table><tr><td rowspan=1 colspan=3>Effect of Perm on Cotinine-Negative Hair Samples</td></tr><tr><td rowspan=1 colspan=1>Sample #</td><td rowspan=1 colspan=1>EIA Result withUntreated Hair</td><td rowspan=1 colspan=1>EIA Result withPermed Hair</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Effect of Relaxer on Cotinine-Negative Hair Samples</td></tr><tr><td rowspan=1 colspan=1>Sample #</td><td rowspan=1 colspan=1>EIA Result withUntreated Hair</td><td rowspan=1 colspan=1>EIA Result with RelaxedHair</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Effect of Dye on Cotinine-NegativeHair Samples</td></tr><tr><td rowspan=1 colspan=1>Sample #</td><td rowspan=1 colspan=1>EIA Result withUntreated Hair</td><td rowspan=1 colspan=1>EIA Result with DyedHair</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr></table>

Effects of Cosmetic Treatments on Cotinine EIA Analysis of Cotinine-Positive Hair Samples   

<table><tr><td rowspan=1 colspan=3>Effect of Shampoo on Cotinine-Negative Hair Samples</td></tr><tr><td rowspan=1 colspan=1>Sample #</td><td rowspan=1 colspan=1>EIA Result withUntreated Hair</td><td rowspan=1 colspan=1>EIA Result after Shampoo</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Effect of Perm on Cotinine-Positive Hair Samples</td></tr><tr><td rowspan=2 colspan=1>Sample #</td><td rowspan=1 colspan=2>Cotinine EIA Results</td></tr><tr><td rowspan=1 colspan=1>EIA Result withUntreated Hair</td><td rowspan=1 colspan=1>EIA Result withPermed Hair</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Effect of Shampoo on Cotinine Positive Samples</td></tr><tr><td rowspan=1 colspan=1>Sample #</td><td rowspan=1 colspan=1>EIA Result withUntreated Hair</td><td rowspan=1 colspan=1>EIA Result withAfter Shampoo</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Effect of Dye on Cotinine-Positive Hair Samples</td></tr><tr><td colspan="1" rowspan="1">Sample #</td><td colspan="1" rowspan="1">EIA Result withUntreated Hair</td><td colspan="1" rowspan="1">EIA Result withDyed Hair</td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="3" rowspan="1">Effect of Relaxer on Cotinine-PositiveHair Samples</td></tr><tr><td colspan="1" rowspan="1">Sample #</td><td colspan="1" rowspan="1">EIA Result withUntreated Hair</td><td colspan="1" rowspan="1">EIA Result withRelaxed Hair</td></tr><tr><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr><tr><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Positive</td></tr></table>

# Specificity of the LC-MS/MS method

An interference study was conducted for the LC-MS/MS method by spiking potential interferents into hair specimens containing cotinine and hydroxycotinine, and the results were compared to hair specimens containing cotinine and hydroxycotinine without potential interferent. There was no significant interference from potential interfering compounds (cotinine and hydroxycotinine were present at $4 0 \ : \mathrm { p g / m g }$ hair), as shown in the below table.

<table><tr><td colspan="1" rowspan="1">Inte rfe re nt Name</td><td colspan="1" rowspan="1">Inte rfe re nt Amount (pg/mg hair)</td></tr><tr><td colspan="1" rowspan="1">Pseudoephedrine</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Phentermine</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">d-Amphetamine</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Methamphetamine</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Triazolam</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Midazolam</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Meprobromate</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Flunitrazepam</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Flurazepam</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Estazolam</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Clobazepam</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Clonazepam</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Methyltestosterone</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Cocaine</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Salicylic acid</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Propoxyphene</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">50,000</td></tr><tr><td colspan="1" rowspan="1">(+/-) Methadone</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">cis-Tramadol</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">20,000</td></tr><tr><td colspan="1" rowspan="1">Gabapentin</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Pregabalin</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Salicylic acid</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Valproic acid</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Vigabatrin</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">(+)-Propoxyphe ne</td><td colspan="1" rowspan="1">1000</td></tr><tr><td colspan="1" rowspan="1">Aripipra zole</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Lacosamide</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Oxcarbazepine</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Rufinamide</td><td colspan="1" rowspan="1">2000</td></tr><tr><td colspan="1" rowspan="1">Warfarin</td><td colspan="1" rowspan="1">200,000</td></tr><tr><td colspan="1" rowspan="1">A lprazola m</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Cimetidine</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Citalopram HBr</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Clonazepa m</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Clopidogrel bisulfate</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">2500</td></tr><tr><td colspan="1" rowspan="1">Fluconazole</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Hydrochlorothia zide</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Lamotrogine</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">L-thyroxine</td><td colspan="1" rowspan="1">250</td></tr><tr><td colspan="1" rowspan="1">Methylphe nida te</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Omeprazole</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Levetiracetam</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Metformin HCl</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Phenobarbita l</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">R(-)-Phenylephrine HCl</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Sertraline HCL</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Topirama te</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Zolpidem tartrate</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Zonisamide</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Levetiracetam</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Amlodipine besylate</td><td colspan="1" rowspan="1">250</td></tr><tr><td colspan="1" rowspan="1">Atorvastatin calcium salt</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Azithromyc in dihydrate</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Bupivaca ine HCl. 1H20</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Cetirizine dihydroc hloride</td><td colspan="1" rowspan="1">2500</td></tr><tr><td colspan="1" rowspan="1">Dimenhydrinate</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Lisinopril dihydrate</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Loratadine</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Montelukast sodium salt</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Pioglitazone hydrochloride</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Prednisolone</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Prednisone</td><td colspan="1" rowspan="1">2500</td></tr><tr><td colspan="1" rowspan="1">Procainamide HCl</td><td colspan="1" rowspan="1">5000</td></tr><tr><td colspan="1" rowspan="1">Simvastatin</td><td colspan="1" rowspan="1">5000</td></tr></table>

# LC-MS/MS: Studies to evaluate environmental contamination

Studies were performed to evaluate environmental contamination. Seven samples of cotinineEIA-negative hair locks were suspended in a large Erlenmeyer flask equipped to draw smoke through the flask from a burning cigarette. All of the washed samples had cotinine less than 100 $\mathrm { { p g / m g } }$ hair.

4. Assay Reportable Range: Not applicable. The screening immunoassay is a qualitative test only.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Controls and calibrators are prepared as a methanolic solution containing cotinine and are traceable to certified cotinine and hydroxycotinine reference materials. Cotinine in methanol was shown to be stable up to 11.5 months.

Sample shipping and storage stability: Six samples containing cotinine (Samples were stored at ambient temperatures in the same collection foil and card-envelope in which they were placed at time of collection) were shipped overnight to another location and returned to the original location by overnight shipping. Six additional samples were tested before and after storage at ambient temperatures for 65 days. Samples were tested by the routine LC-MS/MS procedure both before being shipped and after returning to Psychemedics.

Neither shipping, nor storage for over 2 months, caused significant change in the cotinine EIA results.

The screening immunoassay is a qualitative test only; therefore, a detection limit evaluation is not applicable. See section VII.A.1. above for sensitivity around the immunoassay device cutoff.

# Detection Limit of the LC-MS/MS method

The sponsor performed a study to determine the Lower limit of Quantitation (LLOQ) of the LC-MS/MS assay for cotinine and hydroxycotinine.

The LLOQ is the lowest concentration that meets chromatographic and retention time criteria, and that can be quantitated within $20 \%$ of the expected value. The method LLOQ is $1 0 ~ \mathrm { p g / m g }$ hair for cotinine and hydroxycotinine.

# 7. Assay Cut-Off:

Analytical performance of the device around the claimed cutoff is described in precision section VII.A.1 above.

# B Comparison Studies:

1. Method Comparison:

# Accuracy of the immunoassay screening method

A total of 153 samples were utilized for this study. Subjects were identified for inclusion in the study by screening using an independent screening assay (cotinine in oral fluid). The hair samples were then tested using the Psychemedics Microplate EIA for Cotinine in Hair assay and the Psychemedics LC-MS/MS confirmatory assay, results from both methods were compared. The comparison of Psychemedics Microplate EIA for Cotinine in Hair assay with LC-MS/MS confirmatory assay is shown in the following table.

Summary of Results with Positive and Negative Samples Reweighed and Confirmed without Washing   

<table><tr><td rowspan=2 colspan=1>EIA Result</td><td rowspan=1 colspan=4>LCMSMS Result(pg cotinine/mghair)</td></tr><tr><td rowspan=1 colspan=1>&lt; 100</td><td rowspan=1 colspan=1>100-199</td><td rowspan=1 colspan=1>200 - 300</td><td rowspan=1 colspan=1>&gt; 300</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Discrepant results analysis:   

<table><tr><td rowspan=1 colspan=1>PositiveSample #</td><td rowspan=1 colspan=1>EIA result</td><td rowspan=1 colspan=1>MS Cotinine(pg/mg)</td><td rowspan=1 colspan=1>Comments</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>183</td><td rowspan=3 colspan=1>OHCotinine Cross reactivity is 50%; Sum of Cotinine +OHCotinine &gt; 200 pg/mg</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>187</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>194</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>Sum of Cotinine + OHCotinine = 197 pg/mg;Very close to cutoff</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>2nd weighing of sample below cutoff</td></tr><tr><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>2nd weighing of sample below cutoff</td></tr></table>

# Recovery study for the LC-MS/MS:

The sponsor conducted a study to evaluate recovery for cotinine. For each cotinine concentration tested, 4 individual hair samples were prepared and analyzed. The recovery for cotinine ranged from $9 0 . 1 \mathrm { ~ - ~ } 1 0 0 \%$ of Cotinine and Hydroxycotinine at the 2 hour extraction time of the method.

# Recovery of Cotinine/Hydroxycotinine with 1:10 Trifluoroacetic acid:Methanol in Microwave

<table><tr><td rowspan=1 colspan=1>Sample #</td><td rowspan=1 colspan=1>Time(Hours)</td><td rowspan=1 colspan=1>Cotinine(pg/mg hair)*</td><td rowspan=1 colspan=1>Hydroxycotinine(pg/mg hair)*</td></tr><tr><td rowspan=4 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>410</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>437</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>449</td><td rowspan=1 colspan=1>74</td></tr><tr><td rowspan=1 colspan=1>% @ 2 hrs</td><td rowspan=1 colspan=1>97.3</td><td rowspan=1 colspan=1>175</td></tr><tr><td rowspan=4 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>819</td><td rowspan=1 colspan=1>175</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>985</td><td rowspan=1 colspan=1>205</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1075</td><td rowspan=1 colspan=1>222</td></tr><tr><td rowspan=1 colspan=1>% @ 2 hrs</td><td rowspan=1 colspan=1>91.6</td><td rowspan=1 colspan=1>92.3</td></tr><tr><td rowspan=4 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>352</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>378</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>404</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>% @ 2 hrs</td><td rowspan=1 colspan=1>93.6</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=4 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>391</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>425</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>436</td><td rowspan=1 colspan=1>37</td></tr><tr><td rowspan=1 colspan=1>% @ 2 hrs</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>90.1</td></tr><tr><td rowspan=1 colspan=4>*Cumulative</td></tr></table>

# 2. Matrix Comparison:

Not applicable. The assay is intended for only one sample matrix.

# C Clinical Studie s:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

A balanced selection of scientific literature was provided to support the clinical validity of the cutoff, supporting that the device, as designed, can detect the approximate equivalent of one (1) cigarette smoked per day, every day. In addition, a clinical study was conducted in which 25 non-smokers were recruited, who were exposed to second hand smoke daily in the home setting. The amount of cotinine in the hair of all study subjects was below the confirmatory cutoff for the device, supporting that incidental exposure in these individuals did not result in high enough cotinine hair concentrations to be considered a positive result.

D Clinical Cut-Off: Not applicable.   
E Expected Values/Reference Range: Not applicable.

# VIII Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.